Aurinia Presents Additional Data from Phase Iib Aura-Lv Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks

VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (AUPH)(AUP.TO) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, presented additional data from its global Phase IIB AURA-LV (AURA) study in lupus nephritis (LN) during the 54th European Renal Association-European Dialysis and Transplant Association Congress (ERA-EDTA) in Madrid, Spain. The data were presented yesterday during the late-breaking session by lead author James Tumlin, M.D., a clinical investigator for the study and founder of Southeast Renal Research Institute.